enGene Therapeutics Inc. (ENGN) stock
ENGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends October 31Also trades as ENGNW
$1.72−0.17 (-8.99%)
Close on Nov 17, 2026Market cap $115.27MP/E –Yield 0.00%
enGene Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
enGene Therapeutics's R&D Expenses for the twelve months ending Jul 31, 2026 was $96.26M, up 30.0% year over year. For fiscal 2025 it was $94.48M, up 146.6% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $94.48M | +146.6% |
| FY2024 | Oct 31, 2024 | $38.32M | +132.8% |
| FY2023 | Oct 31, 2023 | $16.46M | +6.4% |
| FY2022 | Oct 31, 2022 | $15.47M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jul 31, 2026 | $20.09M | -11.0% |
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | $22.20M | +9.8% |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | $22.26M | +11.4% |
| Q4 FY2025CQ3 2025 | Oct 31, 2025 | $31.72M | +181.4% |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | $22.58M | +95.5% |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | $20.21M | +105.1% |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | $19.97M | +254.3% |
| Q4 FY2024CQ3 2024 | Oct 31, 2024 | $11.27M | +98.8% |
| Q3 FY2024CQ2 2024 | Jul 31, 2024 | $11.55M | +196.1% |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | $9.86M | +206.5% |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | $5.64M | +53.6% |
| Q4 FY2023CQ3 2023 | Oct 31, 2023 | $5.67M | – |
| Q3 FY2023CQ2 2023 | Jul 31, 2023 | $3.90M | – |
| Q2 FY2023CQ1 2023 | Apr 30, 2023 | $3.22M | – |
| Q1 FY2023CQ4 2022 | Jan 31, 2023 | $3.67M | – |
See a number that looks wrong?